Tags

Type your tag names separated by a space and hit enter

Peripheral beta-adrenergic blockade treatment of parkinsonian tremor.
Ann Neurol. 1984 Oct; 16(4):505-8.AN

Abstract

The effect of nadolol, a peripherally acting beta-adrenergic blocker, on resting, postural, and intention tremor was examined in 8 patients with idiopathic Parkinson's disease whose motor symptoms, other than tremor, were well controlled with conventional medications. In a double-blind, placebo-controlled, crossover design, patients received 80 to 320 mg of nadolol for six weeks while continuing their previous therapeutic regimen. Accelerometer readings showed a 34% reduction (p less than 0.025) in tremor distance, but no change in tremor frequency, during nadolol therapy. Maximum benefit was achieved with a dose of 240 mg, when resting tremor improved 54%, postural tremor 32%, and intention tremor 54%. Physician ratings and patient reports supported the accelerometer results. Nadolol appears to be a safe, effective adjunct to current dopaminergic and anticholinergic therapy for severe tremor in Parkinson's disease.

Authors

No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article

Language

eng

PubMed ID

6149724

Citation

Foster, N L., et al. "Peripheral Beta-adrenergic Blockade Treatment of Parkinsonian Tremor." Annals of Neurology, vol. 16, no. 4, 1984, pp. 505-8.
Foster NL, Newman RP, LeWitt PA, et al. Peripheral beta-adrenergic blockade treatment of parkinsonian tremor. Ann Neurol. 1984;16(4):505-8.
Foster, N. L., Newman, R. P., LeWitt, P. A., Gillespie, M. M., Larsen, T. A., & Chase, T. N. (1984). Peripheral beta-adrenergic blockade treatment of parkinsonian tremor. Annals of Neurology, 16(4), 505-8.
Foster NL, et al. Peripheral Beta-adrenergic Blockade Treatment of Parkinsonian Tremor. Ann Neurol. 1984;16(4):505-8. PubMed PMID: 6149724.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Peripheral beta-adrenergic blockade treatment of parkinsonian tremor. AU - Foster,N L, AU - Newman,R P, AU - LeWitt,P A, AU - Gillespie,M M, AU - Larsen,T A, AU - Chase,T N, PY - 1984/10/1/pubmed PY - 1984/10/1/medline PY - 1984/10/1/entrez SP - 505 EP - 8 JF - Annals of neurology JO - Ann Neurol VL - 16 IS - 4 N2 - The effect of nadolol, a peripherally acting beta-adrenergic blocker, on resting, postural, and intention tremor was examined in 8 patients with idiopathic Parkinson's disease whose motor symptoms, other than tremor, were well controlled with conventional medications. In a double-blind, placebo-controlled, crossover design, patients received 80 to 320 mg of nadolol for six weeks while continuing their previous therapeutic regimen. Accelerometer readings showed a 34% reduction (p less than 0.025) in tremor distance, but no change in tremor frequency, during nadolol therapy. Maximum benefit was achieved with a dose of 240 mg, when resting tremor improved 54%, postural tremor 32%, and intention tremor 54%. Physician ratings and patient reports supported the accelerometer results. Nadolol appears to be a safe, effective adjunct to current dopaminergic and anticholinergic therapy for severe tremor in Parkinson's disease. SN - 0364-5134 UR - https://www.unboundmedicine.com/medline/citation/6149724/Peripheral_beta_adrenergic_blockade_treatment_of_parkinsonian_tremor_ L2 - https://onlinelibrary.wiley.com/resolve/openurl?genre=article&sid=nlm:pubmed&issn=0364-5134&date=1984&volume=16&issue=4&spage=505 DB - PRIME DP - Unbound Medicine ER -